Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine for depression and anxiety in hemodialysis patients
IRCT20220422054611N1Phase 4Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of fluoxetine in major depressive disorder (MDD) and anxiety disorder, sponsored by Kerman University of Medical Sciences. Primary endpoints: Change in severity of depressive symptoms and Change in severity of anxiety symptoms. Started May 2022; status: completed.
02
Drugs
fluoxetine
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on IRCT20220422054611N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220422054611N1.